Virtu KCG Holdings LLC Takes $331,000 Position in Five Prime Therapeutics, Inc. (FPRX)

Virtu KCG Holdings LLC bought a new position in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 11,002 shares of the biotechnology company’s stock, valued at approximately $331,000.

A number of other hedge funds also recently made changes to their positions in the stock. FMR LLC increased its position in Five Prime Therapeutics by 1.8% during the first quarter. FMR LLC now owns 4,343,501 shares of the biotechnology company’s stock worth $157,017,000 after acquiring an additional 77,381 shares during the period. State Street Corp increased its position in Five Prime Therapeutics by 25.7% during the first quarter. State Street Corp now owns 1,249,520 shares of the biotechnology company’s stock worth $45,175,000 after acquiring an additional 255,488 shares during the period. Dimensional Fund Advisors LP increased its position in Five Prime Therapeutics by 11.0% during the first quarter. Dimensional Fund Advisors LP now owns 933,410 shares of the biotechnology company’s stock worth $33,743,000 after acquiring an additional 92,338 shares during the period. BB Biotech AG increased its position in Five Prime Therapeutics by 6.9% during the second quarter. BB Biotech AG now owns 777,500 shares of the biotechnology company’s stock worth $23,411,000 after acquiring an additional 50,000 shares during the period. Finally, Victory Capital Management Inc. increased its position in Five Prime Therapeutics by 28.9% during the second quarter. Victory Capital Management Inc. now owns 666,440 shares of the biotechnology company’s stock worth $20,066,000 after acquiring an additional 149,340 shares during the period. 84.05% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director William R. Ringo sold 2,000 shares of the firm’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $38.00, for a total value of $76,000.00. Following the transaction, the director now owns 2,000 shares in the company, valued at $76,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William R. Ringo sold 1,800 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the transaction, the director now owns 1,200 shares in the company, valued at approximately $48,312. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by company insiders.

A number of equities analysts recently issued reports on FPRX shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $52.00 target price (down previously from $55.00) on shares of Five Prime Therapeutics in a research report on Thursday, August 10th. Zacks Investment Research raised shares of Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Monday. BMO Capital Markets reaffirmed a “hold” rating and set a $39.00 target price on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Royal Bank Of Canada assumed coverage on shares of Five Prime Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $41.00 target price on the stock. Finally, ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $56.29.

TRADEMARK VIOLATION NOTICE: This piece was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/10/18/virtu-kcg-holdings-llc-takes-331000-position-in-five-prime-therapeutics-inc-fprx.html.

Shares of Five Prime Therapeutics, Inc. (FPRX) opened at 46.63 on Wednesday. The firm’s market cap is $1.30 billion. Five Prime Therapeutics, Inc. has a 1-year low of $25.97 and a 1-year high of $60.98. The firm’s 50-day moving average is $36.50 and its 200-day moving average is $31.99.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.43). The firm had revenue of $7.80 million for the quarter, compared to the consensus estimate of $8.32 million. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The firm’s quarterly revenue was down 16.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.49) EPS. On average, analysts anticipate that Five Prime Therapeutics, Inc. will post ($5.29) EPS for the current fiscal year.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply